RECENT NEWS

Hundreds of lives could be saved each year in England, following the introduction of a more sensitive cervical screening test. NHS experts said that there is “potential” to eliminate cervical cancer completely thanks to the change in primary test within the NHS Cervical Cancer Screening Programme, combined with the effectiveness of the HPV vaccine.

A new study, the most comprehensive to date, on the incidence of sepsis and sepsis deaths, was published recently in The Lancet. It confirms that the actual rates are double those previously estimated, and that 20% of global deaths are due to this under-reported but deadly condition. The Global Burden of Sepsis study, led by Dr Kristina Rudd and Dr Mohsen Naghavi of the University of Washington and the Institute of Health Metrics and Evaluation (IHME), is the first to produce data according to age, sex, location, and the underlying cause of sepsis.

UK NEQAS for Blood Coagulation organises a scientific meeting (Clinical and Laboratory Haemostasis) on an annual basis. This comprises presentations from nationally and internationally renowned speakers, in addition to data from survey distributions and open debate on scheme issues. Around 350 delegates have previously attended each year.

Xyall has been identified as a next-generation global innovator in molecular pathology, winning investment of €5 million from partners such as Sioux Technologies, BOM Brabant Ventures, the Netherlands Enterprise Agency, and other private investors.

Oxford Gene Technology (OGT), a Sysmex Group company, has launched its SureSeq CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing (NGS) offering for research into chronic lymphocytic leukaemia (CLL). The SureSeq CLL + CNV Panel fulfils the desire for reliable copy number variation (CNV) detection by NGS, including trisomy 12 and loss of heterozygosity (LOH), as well as somatic variants, even at low allele frequency. The comprehensive panel covers all the most up-to-date, evidence-based genes and genomic aberrations for CLL, and will enable laboratories to simplify their laboratory workflow by replacing multiple assays with a single one.

Diagnosis of infectious diseases such as influenza is seeing a sea change due to technological innovations and development of next-generation molecular tests such as nuclear acid amplification tests (NAATs) and advanced immunoassays. The global rapid influenza diagnostic tests market size is expected to grow over 8% compound annual growth rate during the forecast period (2019–2029).

FFEI, a global developer of award-winning digital imaging solutions, has appointed Paul Bulpitt as Head of Research & Development. This is a new role within FFEI, reflecting the company’s continued growth in developing innovative digital imaging projects. Paul will be responsible both for FFEI’s life sciences and digital inkjet business R&D teams, to drive the development of world-beating products for its growing number of client-based projects.

Norfolk and Norwich University Hospitals NHS Foundation Trust (NNUH) has selected Swiss Post Solutions (SPS) to deliver a digital transformation solution across the trust. SPS chose IMMJ Systems to provide the Electronic Document Management (EDM) component of the overall solution, and their implementation expertise to deliver MediViewer, a next-generation digital platform enabling clinical EDMS to provide digitised clinical content and full electronic patient records at the point of care.

The 35th British Society for Microbial Technology (BSMT) Annual Scientific Conference will be held on Thursday 14 May 2020 at the RAF Museum, Hendon, entitled The Genomic and Molecular Revolution in Microbiology: In Technology We Trust (or do we?). The theme of the conference is designed to explore how the molecular revolution in microbiology has been useful in improving patient care, and the BSMT committee organising the conference have developed a full programme of excellent speakers and relevant topics.

The February issue of Pathology in Practice will see publication of the ninth and final article in Dr Stephen MacDonald’s series on internal quality control (IQC). Here, he looks at the actions needed when processes deviate beyond expected variation, and the troubleshooting of IQC failure, which concludes the series on statistical quality control (SQC).

The NHS in England is providing a new form of DNA test capable of rapidly diagnosing rare diseases for critically ill babies and children, as part of its Long Term Plan to use world-leading technologies to improve care for the sickest infants.

The National Collection of Type Cultures (NCTC) is one of the longest established collections of microorganisms in the world; its cultures reflect the history of clinical bacterial infections from the end of the 19th century to the present day. Set up in 1920 to “provide a trustworthy source of authentic bacteria for use in scientific studies”, the remit for NCTC has remained essentially unchanged.

Health research faces a crisis that could impact on patient care, says a new report led by 10 prominent figures in the NHS and academia. The Academy of Medical Sciences’ report raises the alarm about the number of research-active NHS staff who are finding it increasingly difficult to find time for research. Support for research is not helped by the widening gap between universities and the NHS.

Lipoprotein(a) (Lp[a]) is a modified atherogenic low-density lipoprotein particle containing apolipoprotein(a) (apo[a]). Although Lp(a) is considered to be a causal risk factor and independent genetic marker of cardiovascular disease (CVD), there is little consensus between the different national guidelines on how to use the information provided to estimate this risk accurately.

MediSieve is the medical device company developing ‘magnetic blood filtration’. Its technology can potentially transform the treatment of bloodborne diseases including sepsis, leukaemia and malaria in a process that is similar to dialysis.  Dr George Frodsham, CEO and founder of MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.

Beckman Coulter has announced that South West London Pathology (SWLP) has implemented DxH 900 haematology analysers and the Early Sepsis Indicator across the SWLP network. SWLP is an award-winning NHS pathology partnership set up by St George’s University Hospitals NHS Foundation Trust, Croydon Health Services NHS Trust and Kingston Hospital NHS Foundation Trust. The installation enables SWLP laboratories to provide a single, integrated pathology service to more than 3.5 million people across South West London via three hospitals, 200 GP practices and 30 community healthcare sites.

Syngene is now supplying the AirClean AC600 Series of polymerase chain reaction (PCR) workstations. Some of the workstations include high-efficiency particulate air (HEPA) filtration and all use ultraviolet (UV) irradiation to minimise the risk of airborne DNA contamination, saving scientists time by producing consistent quality DNA from their PCR.

Oxford Gene Technology (OGT), a Sysmex Group company, has developed a breakthrough targeted next-generation sequencing (NGS) panel for constitutional cytogenetics research. The new CytoSure NGS panel – to be launched early in 2020 – will combine the strengths of microarrays and NGS to deliver a comprehensive all-in-one assay.

Mast Group has announced the expansion of its molecular product portfolio with the launch of the new MAST ISOPLEX CRE-ART kit for the rapid molecular detection of carbapenemase-producing organisms (CPOs).

The Process Analytics unit of Hamilton Bonaduz has enjoyed a successful anniversary year. Not only did measurement experts participate in various events but also introduced three new products to the market. The long-awaited Incyte Arc sensor for measuring viable cell density was introduced at the ESACT conference in Copenhagen.